(April 13, 2018, 1:04 PM EDT) -- NEWARK, N.J. — A diagnostics company that develops proprietary genomic tests and services and certain of its current and former executive officers violated federal securities laws by concealing the company’s business, operational and compliance policies, a shareholder argues in an April 12 securities class action complaint filed in New Jersey federal court (Ruo Fen Zhang v. Cancer Genetics Inc., et al., No. 18-6353, D. N.J.)....